Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
iPark Institute is planning an expansion of the science park it manages, Shonan Health Innovation Park (Shonan iPark), as early as FY2028 in order to meet the growing needs of tenants, President Toshio Fujimoto said on October 11. Although still…
To read the full story
Related Article
- Shonan iPark to Drive Japan Approval of New Drugs from Korean Biotechs
February 26, 2025
- Shonan iPark Commences Full-Fledged Operations in South Korea
July 16, 2024
- Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
October 13, 2023
BUSINESS
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
- Alfresa Launches Neffy Nasal Spray for Anaphylaxis in Japan
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Teijin Seeks Japan Nod for Ascendis’s GHD Drug
February 13, 2026
- Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…